| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10158360 | Biomedicine & Pharmacotherapy | 2018 | 8 Pages |
Abstract
Silibinin can ameliorate some metabolic alterations and induce some molecular changes by activating the CFLAR-JNK pathway and thereby regulating its downstream target genes involved in lipid metabolism (PPARα, SREBP-1C and PNPLA3), glucose uptake (PI3K-AKT), oxidative stress (NRF2, CYP2E1, CYP4A) and inflammatory response(NO) in OA-treated HepG2 cells demonstrating its possible use in ameliorating various symptoms of NASH.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yayun Liu, Qingqing Yu, Yong Chen,